Evidence map›Paper›PMID 40883614›Full record

ArticleBone marrow transplantation2025

Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT.

Noureddine Henoun Loukili, Luuk Gras, Linda Koster, Didier Blaise, Tobias Gedde-Dahl, Johan Maertens, Lone Smidstrup Friis, Stephan Mielke, Patrice Chevallier, Jakob R Passweg and 13 more

Abstract read
In one paragraph

Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Noureddine Henoun LoukiliCHU de Lille, Lille, France. Noureddine.henounloukili@chu-lille.fr.ORCID 0000-0002-8677-7392
Luuk GrasEBMT Leiden Study Unit, Leiden, the Netherlands.
Linda KosterEBMT Leiden Study Unit, Leiden, the Netherlands.
Didier BlaiseInstitut Paoli Calmettes, Marseille, France.ORCID 0000-0002-5684-9447
Tobias Gedde-DahlOslo University Hospital, Oslo, Norway.
Johan MaertensUZ Gasthuisberg, Leuven, Belgium.ORCID 0000-0003-4257-5980
Lone Smidstrup FriisUniversity Hospital, Rigshospitalet, and Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Stephan MielkeDepartment of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Institute & University Hospital, Stockholm, Stockholms Laen, Sweden.ORCID 0000-0002-8325-9215
Patrice ChevallierCHU de NANTES, Nantes Cedex 1, Nantes, France.ORCID 0000-0003-3142-5581
Jakob R PasswegUniversity Hospital, Basel, Switzerland.ORCID 0000-0001-7092-3351
Jennifer Louise ByrneNottingham University, Nottingham, UK.
Urpu SalmenniemiDepartment of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Patrice CeballosCHU Montpellier, Montpellier, France.
Jérôme CornillonInstitut de Cancerologie Lucien Neuwirth, CHU Saint Etienne, Saint Etienne, France.
Simona SicaSezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.ORCID 0000-0003-2426-3465
Francesco OnidaFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico - University of, Milan, Italy.ORCID 0000-0002-2991-3474
Christof ScheidUniversity of Cologne, Koeln, Germany.
Carmelo GurnariDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH &Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.ORCID 0000-0001-6829-5544
Joanna Drozd-SokolowskaCentral Clinical Hospital, The Medical University of Warsaw, Warsaw, Poland.ORCID 0000-0002-4562-6264
Kavita RajUniversity College London Hospitals NHS Trust, London, UK.ORCID 0000-0002-8258-354X
Marie RobinHôpital Saint-Louis, APHP, Université de Paris Cité, Paris, France.ORCID 0000-0003-1388-9876
Donal P McLornanUniversity College London Hospitals NHS Trust, London, UK.ORCID 0000-0003-1224-091X
Ibrahim Yakoub-AghaCHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000, Lille, France.ORCID 0000-0003-4524-8782

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reduced intensity conditioning (RIC) is usually used for patients with myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (allo-HCT), particularly in the elderly or those with comorbidities. The impact of conditioning intensity on patients' outcome remains controversial with clinicians' subjective opinion/ experience remaining a major guide in choosing the intensity. Here, we compare RIC versus MAC in a large EBMT retrospective study in MDS patients aged ≥50 years undergoing allo-HCT between 2014 and 2018. Among the 1393 included patients, 922 (66%) were males, and the median age at transplant was 62.8 (50.0-77.9) years. The majority of patients (n = 884; 64.3%) had MDS with excess blasts. IPSS-R recorded was very low/low (n = 598, 43%), intermediate (n = 352, 25%), and high/very high (n = 443, 32%). Karnofsky index was ≥90 in 916 (69.3%) patients, and HCT-CI ≥ 3 in 292(27.3%) patients. A RIC regimen was used in 1053 (75.5%) patients. Median follow-up was 27.9 months (IQR: 26.4-30.6). Both uni- and multi-variable analyses did not show any significant association between conditioning intensity and outcomes. This study highlights a lack of association between RIC/MAC regimens and outcomes in allo-HCT MDS patients. Our results support the recently published systematic review and meta-analysis, where evidence for using one conditioning regimen over another remains weak.

Indexed as

Hematopoietic Stem Cell TransplantationMyelodysplastic SyndromesTransplantation ConditioningAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTransplantation, Homologous

Identifiers

PMID40883614
PMCPMC12583188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.